A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and GLP-1 receptor) in persons with MASH and liver fibrosis are unclear. METHODS: In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo. The trial had two phases: a 24-week rapid-dose-escalation phase, followed by a 24-week maintenance phase. The primary end point was histologic improvement (reduction) in MASH with no worsening of fibrosis. Secondary end points included a decrease in liver fat content by at least 30% and biopsy-assessed improvement (reduction) in fibrosis by at least one stage. RESULTS: A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model). A decrease in liver fat content by at least 30% occurred in 63% of the participants in the survodutide 2.4-mg group, 67% of those in the 4.8-mg group, 57% of those in the 6.0-mg group, and 14% of those in the placebo group; improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively. Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%); serious adverse events occurred in 8% with survodutide and 7% with placebo. CONCLUSIONS: Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis, warranting further investigation in phase 3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number, NCT04771273; EudraCT number, 2020-002723-11.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationChanging epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522
Self-citationGlucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Cited by
Items 101–200 of 537
Gastaldelli, A., & Newsome, P. N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf094 · Cited by 29
Self-citationMuzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
History of glucagon-like peptide-1 receptor agonists
Darwish, R., Abu-Sharia, G., & Butler, A. E. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108045 · Cited by 29
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
Triple Agonism Based Therapies for Obesity
Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00770-z · Cited by 22
“Additionally, in phase 2 studies in people with MASH and liver fibrosis, survodutide not only significantly improved liver steatosis, but also led to histologic improvement of MASH without worsening fibrosis in 43–62% of participants, versus 14% with placebo [41].”
Kakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 28
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 29
“While survodutide, an investigational long-acting dual agonist of glucagon and GLP-1 receptors, also exhibited potential for enhancing MASH in a similar trial [188].”
Caussy, C., Cusi, K. J., Rosenstock, J., Bugianesi, E., Thomas, M. K., Tang, Y., Mather, K. J., Loomba, R., Sanyal, A. J., & Hartman, M. L. (2025) · Diabetes Care · doi:10.2337/dc25-1306 · Cited by 33
“A phase 2 trial of survodutide, a GLP-1 and glucagon receptor agonist, demonstrated significant improvement in MASH without worsening of fibrosis compared with placebo (11).”
Self-citationLanger, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102665 · Cited by 21
Tamilwanan, S., Aziz, Z., Rong, L. Y., Bitar, A. N., Zarzour, R. A., & Alshehade, S. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04358-0 · Cited by 26
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 24
“New data have also been published from phase 2 trials with tirzepatide (dual GIP/GLP-1 RA) [121] and survodutide (dual Glucagon/GLP-1 RA) [122] with improvement of fibrosis in F2/F3 stages.”
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
Khan, M. S., Javaid, S. S., Dinani, A. M., Wegermann, K., Pandey, A., Bhatt, A. S., Muthiah, M. D., Spall, H. G. C. V., Zannad, F. M., Butler, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.100 · Cited by 27
Chen, L., Horn, P., & Tacke, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70545 · Cited by 23
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 32
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
“Another two GLP1R/GCGR dual agonists, Pemvidutide [152] and Survodutide [153], are under evaluation for NAFLD/NASH in phase I and II trials, respectively (NCT05006885 and NCT04771273).”
Bharaj, I. S., Brar, A. S., Kahlon, J., Singh, A., Hotwani, P., Kumar, V., Sohal, A., & Batta, A. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i6.106147 · Cited by 19
Shantaram, D., Rima, X. Y., Bradley, D. P., Liu, J. Z., Wright, V. P., AMARI, A., Jalilvand, A., Rottinghaus, J., Fernandes, J. M., Smith, A. J., et al. (2025) · Diabetes · doi:10.2337/db24-0861 · Cited by 18
Screening for advanced steatotic liver disease
Johansen, S., Åberg, F. O., Tsochatzis, E. A., & Krag, A. A. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00097-4 · Cited by 20
Oxyntomodulin physiology and its therapeutic development in obesity and associated complications
Kueh, M. T. W., Chong, M. C., Miras, A. D., & le Roux, C. W. (2024) · The Journal of Physiology · doi:10.1113/jp287407 · Cited by 24
“%) but not on liver fat reduction (greatest reduction of ∼ 67% seen in 4.8 mg group) (Sanyal et al., 2024).”
InfluentialProglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Kaplan, L. M., Startseva, E., le Roux, C. W., Wharton, S., Bozkurt, B., Mazo, D. F. D. C., von Schlippenbach, J., Maldonado, S. G., Hussain, S. A., Neff, G. W., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04479-3 · Cited by 29
“In phase 2 trials, survodutide treatment was shown to improve histological MASH and liver fibrosis and reduce LFC in participants with biopsy-confirmed MASH 24 and to induce significant weight reduction in participants with obesity with or without type 2 diabetes (T2D) 25,26 .”
InfluentialSelf-citationRecent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
Glucagon controls obesity-specific energy expenditure via persistent cAMP/PKA signaling
Long, F., Challa, T. D., Ding, L., Sharma, A. K., Wu, C., Ghosh, A., Noé, F., Horváth, C., Liebisch, G., Höring, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.011 · Cited by 17
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 21
New drug therapies for metabolic dysfunction-associated steatohepatitis
Chiang, J. Y. L. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.001 · Cited by 19
Huber, Y., Hofmann, L. J., Prochaska, J. H., Koeck, T., Chalabi, J., Pfeiffer, N., Beutel, M. E., Strauch, K., Lackner, K. J., Tuescher, O., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70053 · Cited by 19
Self-citationGrocic, M., Nguyen, M., & Sanyal, A. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70662 · Cited by 19
Self-citationMolecular Pharmacology of Vitamin C and Relevance to Health and Obesity—A Narrative Review
Wilson, R. B., Liang, Y., Kaushal, D., & Carr, A. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147523 · Cited by 21
“This is reflected in the substantial improvement in NASH after treatment with metabolic bariatric surgery, GLP-1R agonists (semaglutide), glucagon receptor/GLP-1R dual agonists (survodutide), or specific hepatic thyroid hormone receptor β agonists (resmetirom) [83–86].”
BackgroundWeight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Bernhard, J., Galli, L., Speidl, W. S., & Krychtiuk, K. A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02185-5 · Cited by 19
“In patients with biopsy-confirmed MASH with fibrosis, one year treatment with survodutide was superior to placebo with respect to improvement in MASH without worsening of liver fibrosis [78].”
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“In a phase II clinical trial of patients with biopsy-confirmed MASH, treatment with survodutide significantly reduced liver fat content and improved MASH without worsening of fibrosis by up to 62% 164 .”
Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation
John, S., Bhowmick, K., Park, A., Huang, H., Yang, X., & Mishra, L. (2025) · Bioelectronic Medicine · doi:10.1186/s42234-025-00172-x · Cited by 15
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 15
Qiu, Y., Laguna, J. C., Alegret, M., & Vilà, L. (2026) · Nutrients · doi:10.3390/nu18040679 · Cited by 16
“In a study with survodutide, a dual GLP-1/glucagon receptor agonist, 83% of participants achieved improvement in MASH with no worsening in fibrosis, and 64% of participants with F2–3 fibrosis had ≥ 1 stage improvement of fibrosis without worsening of MASH [216].”
Expanding applications of therapies based on GLP1
Drucker, D. J. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01066-9 · Cited by 18
Jin, L., Zhu, W., Hu, X., Lin, Y., Lou, S., Zhang, Q., Wang, M., Ye, B., Min, J., Wang, Y., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01444-4 · Cited by 15
“Recently, the phase 2 clinical trial of survodutide showed the potential ef fi cacy against MASH [5], and this year, the FDA of US just approved the fi rst anti-MASH drug resmetirom [6].”
Liu, C., Zeng, Q., Hu, T., Huang, Y., Song, Y., Guan, H., Rockey, D. C., Tang, H. C., & Li, S. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.100 · Cited by 15
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
“145”
Liu, L., Xia, Y., Wang, B., & Zhang, Y. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70084 · Cited by 13
Abu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 16
“GLP-1R agonists are known to have beneficial effects in this large and steadily growing patient population, primarily through their effects on weight loss and insulin secretion, although emerging evidence suggests direct hepatic effects as well [152, 153].”
Tornea, D. A., Goldiș, C., Isaic, A., Motofelea, A. C., Sima, A. C., Ciocârlie, T., Crintea, A., Diaconescu, R. G., Motofelea, N., & Goldiș, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010086 · Cited by 13
“Eight studies [14,16,20,29–33] included patients with MASH, while four studies [15,25,26,31] included patients without type 2 diabetes.”
InfluentialPreventing the progression of cirrhosis to decompensation and death
Villanueva, C., Tripathi, D., & Bosch, J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01031-x · Cited by 40
“…involving patients with MASH, mainly with F2 to F3 fibrosis, two dual GLP1RAs (also targeting — in addition to the GLP1 receptor — the glucagon receptor or the glucose-dependent insulinotropic peptide receptor) have shown efficacy in MASH resolution and the potential to improve fibrosis 35,36 .”
Incretin-Based Therapies and Cancer: What’s New?
Medenica, S., Bogdanović, J. M., Vekić, J., Vojinović, T., Babić, I., Bogdanovic, L. M., Maggio, V., El‐Tanani, M., & Rizzo, M. (2025) · Medicina · doi:10.3390/medicina61040678 · Cited by 13
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
“117 In this study, paired biopsy data indicated that resolution of MASH without worsening of fibrosis occurred in up to 64.5% of participants with F2 or F3 fibrosis receiving survo-dutide compared with 13.0% of those receiving placebo, while improvement in liver fibrosis with no worsening of MASH…”
InfluentialSelf-citationThe National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Júnior, W. S. D. S., Sposito, A. C., & Godoy‐Matos, A. F. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.034 · Cited by 12
Opportunistic Screening of Chronic Liver Disease with Deep-Learning–Enhanced Echocardiography
Sahashi, Y., Vukadinovic, M., Amrollahi, F., Trivedi, H. D., Rhee, J., Chen, J. H., Cheng, S. C., Ouyang, D., & Kwan, A. C. (2025) · NEJM AI · doi:10.1056/aioa2400948 · Cited by 14
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic
Suzuki, H., Fujiwara, N., Singal, A. G., Baumert, T. F., Chung, R. T., Kawaguchi, T., & Hoshida, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001227 · Cited by 18
Lean MASLD and Cardiovascular Disease: A Review
Lebovics, N., Heering, G., Frishman, W. H., & Lebovics, E. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000893 · Cited by 13
Simeone, P., Costantino, S., Liani, R., Tripaldi, R., Castelnuovo, A. F. D., Tartaro, A., Mengozzi, A., Cosentino, F., Cipollone, F., Consoli, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02706-8 · Cited by 12
“A beneficial effect on metabolic associated steato-hepatitis has been also recently reported in phase II trials with dual GIP and GLP-1RA [41] or dual glucagon and GLP-1RA [42].”
Proteomic signatures reflect effects of semaglutide treatment for MASH
Schattenberg, J. M., Grønbæk, H., Kliers, I., Ladelund, S., Long, M. T., Nygård, S. B., Sanyal, A. J., & Davies, M. J. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101521 · Cited by 14
“14,15 Limitations included a lack of liver histologic data in the STEP program, therefore there is a possibility that some participants could have been mis-classified in terms of fibrosis staging.”
Self-citationStachteas, P., Nasoufidou, A., Karakasis, P., Koiliari, M., Karagiannidis, E., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39691 · Cited by 11
Glucagon Receptor Deficiency Causes Early-Onset Hepatic Steatosis
Cacciottolo, T. M., Lawler, K., Méndez-Acevedo, K. M., de Oliveira, E. M., Syanda, A. M., Henning, E., Keogh, J. M., Bounds, R., Smith, M., Ashraf, D., et al. (2025) · Diabetes · doi:10.2337/db25-0209 · Cited by 13
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
Why do obesity drugs seem to treat so many other ailments?
Lenharo, M. (2024) · Nature · doi:10.1038/d41586-024-03074-1 · Cited by 17
le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., Hussain, S. A., & Hennige, A. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16167 · Cited by 12
“…reduction associated with survodutide occurred across a range of participant subgroups, and the observed effects of survodutide in modifying cardiometabolic parameters, 22,28 suggest wider population benefit, but females and those with a lower BMI may achieve more weight loss with survodutide.”
Self-citationImpact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis
Takawy, M., & Abdelmalek, M. F. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01579-1 · Cited by 14
“…GLP-1RAs in patients with MASLD/MASH include gastrointestinal symptoms (nausea, vomiting diarrhea, constipation or abdominal discomfort), a profile consistent with that observed in previous phase 3 clinical trials involving patients with T2DM, obesity or both [110, 112–114, 120, 122–124, 126–129].”
InfluentialWang, Y., Chen, Z., Wei, B., Zhang, R., Zhang, X., & Xu, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-90667-z · Cited by 10
Oxyntomodulin - past, present and future
Holst, J. J., & ROSENKILDE, M. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171393 · Cited by 12
“A third phase 2 trial included people with metabolic dysfunction-associated steatohepatitis (MASH) and showed improvements in MASH and liver fibrosis after 48 weeks [65].”
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Li, G., Wong, V. W., Chan, R., Sin, D. M.-C., Chu, C. W., Wong, V., Cheung, C., Lam, S., Lin, H., Yeung, S. S. Y., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00032-3 · Cited by 10
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 12
“The main side effects are gastrointestinal (diarrhea, constipation, nausea and vomiting) [79–81, 84, 85], although headache, fatigue, arthralgia and loss of appetite were also reported.”
From pathophysiology to novel approaches for obesity-associated hypertension
Kanbay, M., Yayci, E., Genc, C., Çöpür, S., Aktaş, Ö. Y., Sarafidis, P. A., Covic, A. C., Ortíz, A., & Laffin, L. J. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf218 · Cited by 12
“Moreover, it reduced DBP by 2.98 ± 7.83 mmHg, 1.30 ± 9.80 mmHg and 1.33 ± 7.77 mmHg, respectively [80 ].”
InfluentialResearch and application of medicines for treating liver fibrosis: current status and prospects
Chen, S., Wu, Z., Zhang, J., Lin, Y., Xie, J., Yin, D., & Zhu, Y. H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1582258 · Cited by 13
Zhou, Y., Tu, L., Wang, X., Xu, J., Xu, S., Ning, X., Xiong, X., & Zheng, N. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01399 · Cited by 10
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 12
Das, S., Agarwal, K., Kapoor, N., Lakhani, O., & Gupta, A. D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000935 · Cited by 10
Borges, R. D. S., de Abreu, E. S., Berton, G. G., de Paula, L. H., Conegundes, A. F., Martins, J. M. B., Martins, M. A. B., Dahbour, A., Fernandes, M. V., & Abdelmalek, M. F. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101708 · Cited by 14
“…in the ESSENCE, 29 SYNERGY-NASH, 31 News-ome et al. , 28 and LEAN 27 studies, and a single pathologist in the studies from Sanyal et al. 32 and Loomba et al. 30 Because the included studies enrolled patients across a wide spectrum of fibrosis (F0–F4), who may exhibit clinical and…”
InfluentialZhi, Y., Dong, Y., Li, X., Zhong, W., Lei, X., Tang, J. T., & Mao, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3846 · Cited by 10
“In this trial, up to 83% of participants achieved improvement in MASH with no worsening in fibrosis, and 64% of participants with F2–3 fibrosis had ≥ 1 stage resolution of fibrosis without worsening of MASH [137].”
Does Incretin Agonism Have Sustainable Efficacy?
Janket, S., Chatanaka, M. K., Sohaei, D., Tamimi, F., Meurman, J. H., & Diamandis, E. P. (2024) · Cells · doi:10.3390/cells13221842 · Cited by 11
Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes
Wu, Y., Chan, A. Y., Hauke, J., Aung, O. H., Foollee, A., Cleofe, M. A. S., Stölting, H., Han, M., Jeppe, K. J., Barlow, C. K., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102064 · Cited by 10
MASH to cirrhosis: bridging the gaps in MASLD management
Gadi, Z., Kwanten, W. J., Vonghia, L., & Francque, S. (2024) · Acta Clinica Belgica · doi:10.1080/17843286.2025.2466011 · Cited by 12
“…and obesity, and survodutide, a GLP-1 and glucagon receptor agonist, showed substantial impact on MASH resolution in phase 2 studies, but in intention-to-treat, the numerical trends on fibrosis regression were statistically not significant and will be further evaluated in phase 3 trials [49,50].”
Gholami, M., Balajam, N. Z., Rakhsha, S. S., Sajjadi‐Jazi, S. M., Shafiee, G., & Heshmat, R. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01604-w · Cited by 9
“It also led to a marked reduction in liver fat content and fibrosis improvement in a portion of participants, highlighting its potential as a treatment for MASLD [23].”
Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF
Doiron, J. E., Elbatreek, M. H., Xia, H., Yu, X., Gehred, N., Gromova, T., Chen, J., Driver, I. H., Muraoka, N., Jensen, M. B., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.011 · Cited by 12
Eid, R. A., Hamed, A. M., Elgendy, S. O., Orayj, K. M., Ibrahim, A. S., Hamied, A. M. A., Wahsh, E. A., Youssif, M., Rabea, H., Madney, Y. M., et al. (2025) · Metabolites · doi:10.3390/metabo16010025 · Cited by 9
Malandris, K., Charalampidis, K., Loomba, R. S., & Sinakos, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01621-w · Cited by 12
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
Александровна, П. В., & Okovityi, S. V. (2026) · Biomedicines · doi:10.3390/biomedicines14040909 · Cited by 10
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“Fibrosis improvement by at least one stage was observed in 34%, 36%, 34%, and 22% of participants, respectively [78].”
Wan, H., Xu, N., Wang, L., Liu, Y., Fatahi, S., Sohouli, M. H., & Guimarães, N. S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01501-x · Cited by 8
Woodard, J. S., Velji-Ibrahim, J., & Abrams, G. A. (2024) · Diseases · doi:10.3390/diseases12110288 · Cited by 8
“Phase 2 trials with liver-directed mechanisms (Efruxifermin, Pegozafermin) that target FGF-21 or weight-loss combinations of GLP-1/GIP/Glucagon (Tirzepatide, Survodutide) have shown improvement in liver fibrosis and are currently in phase 3 investigations [17–20].”
le Roux, C. W., Steen, O., Lucas, K. J., Ekinci, E. I., Startseva, E., Unseld, A., Hussain, S. A., & Hennige, A. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16052 · Cited by 9
Self-citationGuía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502442 · Cited by 9
Messer, E. K., Petroff, D., Schattenberg, J. M., Zeuzem, S., von der Ohe, M., Ludwig, L., Demir, M., Buggisch, P., Stein, K., Serfert, Y., et al. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2592-6109 · Cited by 11
Self-citationHartman, M. L., Loomba, R. S., Lawitz, E., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Tang, Y., Brouwers, B., Bunck, M. C. M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101472 · Cited by 10
Self-citationLee, B. K., Ghumman, U., Pedicone, L. D., Gómez-Aldana, A., & Lawitz, E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0337 · Cited by 11
Self-citationFiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
Obesity Medication Treatment Perspectives Among People with Overweight or Obesity
Ostrominski, J. W., Chhibber, A., Kuti, E. L., Clark, B. J., & Donato, B. M. K. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s555622 · Cited by 8
“34,35 Although the uptake of GLP-1RA-based therapies has been rapid, 36 and OMs are increasingly recommended in clinical practice guidelines as part of comprehensive strategies to address important health risks in people with obesity (PwO), their adoption and utilization remains low, with only 1%…”
Li, M., Hu, J., Chin, Y. H., Chew, H. S. J., & Wang, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1681965 · Cited by 9
le Roux, C. W., Wharton, S., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70196 · Cited by 9
“…of evidence from phase 1 and 2 trials in healthy individuals and people with obesity, T2D, and/or MASH that encompassed these doses, 23 – 25 , 28 as well as Assessment of participants occurs onsite or remotely every 2 – 4 weeks during dose escalation and every 6 weeks thereafter until Week…”
Self-citationImmunometabolic integration in therapeutic strategies for managing MASLD
González-Serrano, S., Onoiu, A.-I., Camps, J., & Joven, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1693753 · Cited by 8
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 11
“Main side effect were gastrointestinal [60].”
Tamaki, N., Kimura, T., Wakabayashi, S., Yamazaki, T., Iwadare, T., Tanaka, N., & Kurosaki, M. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01930-2 · Cited by 11
“Similarly, the dual GLP-1/glucagon receptor agonist survodutide demonstrated MASH resolution in 43–62% of patients compared to 14% for placebo [93].”
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
“By combining GLP-1 – mediated appetite suppression with glucagon-driven energy expenditure and lipid oxidation increases, survodutide resulted in significant weight reductions (up to (cid:0) 14.9% at 46 weeks) [45], as well as compelling reductions in liver fat (at least 30% at 48 weeks) [44].”
InfluentialReinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 12
Metadata
- Authors
- Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., Hosseini-Tabatabaei, A., Schattenberg, J. M., Noureddin, M., Alkhouri, N., & Younes, R.
- Affiliations
- Inserm (FR)
- From the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); Liverpat and University of Paris (P.B.), and Sorbonne Université, Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris, INSERM Unité Mixte de Recherche Scientifique 1138, Centre de Recherche des Cordeliers (V.R.) — all in Paris; Boehringer Ingelheim, Ingelheim am Rhein (M.F., S.A.H and R.Y.), Saarland University Medical Center, Homburg (J.M.S.), and University of the Saarland, Saarbrücken (J.M.S.) — all in Germany; Covenant Metabolic Specialists, Sarasota, FL (G.W.N.); Houston Methodist Hospital and Houston Research Institute, Houston (M.N.), and the Texas Liver Institute, University of Texas Health San Antonio, San Antonio (E.L. and N.A.) — all in Texas; the University of Turin, Turin, Italy (E.B.); the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, and Newcastle National Institut...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 311-319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399439504
- Cited by
- 528
- References
- 28
- Citations by year
- 2026: 212 · 2025: 237 · 2024: 79
- FWCI
- 159.28
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- survodutide, nonalcoholic steatohepatitis, liver fibrosis, glucagon receptor agonist, GLP-1 receptor agonists, liver fat, histologic improvement, dose-response relationship, adverse events, non-alcoholic fatty liver disease, drug safety and efficacy, dose escalation, maintenance phase
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Receptors, Glucagon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.